tifluadom has been researched along with naltrexone in 8 studies
| Studies (tifluadom) | Trials (tifluadom) | Recent Studies (post-2010) (tifluadom) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 78 | 0 | 0 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | tifluadom (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craft, RM; Dykstra, LA | 2 |
| Jackson, HC; Kitchen, I | 1 |
| Smith, CB | 1 |
| Hayes, AG; Stewart, BR | 1 |
| Hayes, AG; Skingle, M; Tyers, MB | 1 |
| Jackson, HC; Sewell, RD | 1 |
| Heyliger, SO; Jackson, C; Rice, KC; Rothman, RB | 1 |
8 other study(ies) available for tifluadom and naltrexone
| Article | Year |
|---|---|
Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Behavior, Animal; Benzodiazepines; Benzomorphans; Drug Interactions; Ethylketocyclazocine; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Saimiri; Urination | 1992 |
Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Benzodiazepines; Benzomorphans; Drug Interactions; Drug Tolerance; Ethylketocyclazocine; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Saimiri; Shock; Time Factors | 1992 |
Effects of opioid agonists on urine production in neonatal rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Animals, Newborn; Benzodiazepines; Body Weight; Female; Male; Morphine; Naltrexone; Narcotics; Phentolamine; Pyrrolidines; Rats; Rats, Inbred Strains; Urodynamics | 1989 |
New approaches to the evaluation of opioid agonists and antagonists upon the isolated, electrically stimulated mouse vas deferens preparation.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzodiazepines; Benzomorphans; Enkephalin, D-Penicillamine (2,5)-; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalins; Male; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Oligopeptides; Pyrrolidines; Receptors, Opioid; Vas Deferens | 1987 |
Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzodiazepines; Benzomorphans; Corticosterone; Dose-Response Relationship, Drug; Fentanyl; Male; Morphine; Naloxone; Naltrexone; Pyrrolidines; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1985 |
Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzodiazepines; Buprenorphine; Cyclazocine; Ethylketocyclazocine; Fentanyl; Male; Naltrexone; Pain; Pyrrolidines; Rats; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1986 |
The role of opioid receptor sub-types in tifluadom-induced feeding.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Benzomorphans; Convulsants; Eating; Enkephalin, Leucine; Flumazenil; Male; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Stereoisomerism | 1984 |
Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity.
Topics: Animals; Benzeneacetamides; Benzodiazepines; Brain; Caudate Nucleus; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; In Vitro Techniques; Inhibitory Concentration 50; Naltrexone; Oligopeptides; Peptide Fragments; Peptides; Pyrrolidines; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Somatostatin | 1999 |